The global Antacids market worth USD 9.9 Bn. by 2029, growing at a CAGR of 4.5%
.jpg
"The Global Antacids Market 2019-2029 (USD Billion)")
The global antacids market was valued at USD 5,858.4 million in 2019. Increase in prevalence of gastrointestinal diseases, rapidly growing volume of geriatric patient pool, along with rise in cases of heartburn and acid reflux across the globe are key factors driving the global antacids market.
Antacids are used for the treatment of acid reflux, which leads to heartburn, stomach upset, and indigestion. Antacids helps to alleviate heartburn, which is a common symptom of gastro esophageal reflux disease (GERD). Aluminium hydroxide, magnesium calcium carbonate, and magnesium trisilicate are common ingredients of antacids. Aggravating gastric diseases such as gastro esophageal reflux disease (GERD) drives the demand for antacids. GERD is one of the most common gastrointestinal disorders, with a prevalence of approximately 20% of adults in western culture. Moreover, increase in elderly patient pool susceptible to gastric diseases is expected to drive the growth of antacids market in the future. However, adverse effects associated with antacids such as increased risk of toxicity in individuals with renal failure, osteopenia, constipation is expected to hinder the growth of the market over the forecast period.
The global antacids market has been segmented based on dosage form, distribution channel, and region. On the basis of dosage form, tablets segment held the largest share of the global antacids market in 2019 owing to wide adoption and high efficacy than other formulations. By distribution channel, online pharmacies segment is anticipated to grow at a lucrative rate over the forecast period. Geographically, Asia Pacific dominated the global antacids market in 2019 and is expected to be the fastest growing region by 2028.
Key players operating in the global antacids market include Bayer AG, GlaxoSmithKline plc, Pfizer, Inc., Sanofi, Reckitt Benckiser Group plc, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Ltd., and Procter & Gamble among others.
Antacids Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2029 |
| Study Period | 2018-2029 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2029 | USD 9.9 Billion |
| Growth Rate | CAGR of 4.5 % during 2019-2029 |
| Segment Covered | Dosage Form, End User, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Bayer AG, GlaxoSmithKline plc, Pfizer, Inc., Sanofi, Abbott, Reckitt Benckiser Group plc, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Ltd., and Procter & Gamble among others. |
Key Segments of the Global Antacids Market
Dosage Form Overview, (USD Billion)
- Liquid
- Tablet
- Others
End-users Overview, (USD Billion)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Overview,(USD Billion)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Reasons for the study
- Increase in prevalence of gastro esophageal reflux disease (GERD)
- Surging cases of heartburn globally
- Growing elderly patient base
What does the report include?
- The study on the global antacids market includes qualitative insights such as drivers, restraints, challenges and opportunities
- Additionally, the market has been evaluated using the Porter’s Five Forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of dosage form, and distribution channel. Moreover, the study on antacids market provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players operating in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global antacids market is suitable for all the players across the value chain including raw material suppliers, hospitals, clinics, pharmaceutical companies and manufacturers, healthcare organizations, distributors, suppliers and application geeks
- Venture capitalists and investors looking for more information on the future outlook of the global antacids market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global antacids market
Frequently Asked Questions (FAQ) :
The antacids market is growing at a CAGR of 4.5 % over the forecast period.
The major contenders in the global market are Bayer AG, GlaxoSmithKline plc, Pfizer, Inc., Sanofi, Abbott, Reckitt Benckiser Group plc, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Ltd., and Procter & Gamble among others.
The global antacids market is Segmented on the basis of Dosage Form, End User, Regions
Antacids are a class of medicines that have been around for a long time. They were initially the first line of protection against peptic ulcer disease, but proton pump inhibitors revolutionized peptic ulcer disease treatment. Antacids are currently used for the treatment of moderate intermittent gastro esophageal reflux disease (GERD) and heartburn. Antacids are available in various forms such as tablets, suspensions, capsules and others. Gelusil, ENO, Pepto-Bismol, Alka Seltzer, Tums are some of the antacids available in the market. Gastric diseases such as gastro esophageal reflux disease (GERD) leading to heartburn pose huge healthcare burden. It is estimated that GERD is one of the most common gastrointestinal disorders, with a prevalence of approximately 20% of adults in western culture. Rapid rise in prevalence of the disease along with large geriatric patient pool will propel demand for antacids. Moreover, major industry players are also investing in R&D to develop antacids and expand product portfolio. For instance, Dr. Reddy's Laboratories released Omeprazole delayed-release tablets in the U.S. in October 2018, which can be used to treat frequent heartburn.
The global antacids market has been segmented based on dosage form, distribution channel, and region. Based on dosage form, the antacids market is segmented into tablets, liquid, and others. Tablets segment held majority of the market share in 2019 owing to advantages such as high efficacy, easy to store and wide availability of different chewable tablets in the market with various flavors that tend to increase the patient adherence to the medication. However, liquid form of dosage is anticipated to witness lucrative growth in the coming years as it is preferred choice among children and elderly patient pool.
On the basis on distribution channel, the global antacids market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. Retail pharmacies held substantial share of the market in 2019 owing to easy accessibility and availability across the globe. Antacids are also available over-the-counter, allowing people to self-medicate their acid reflux symptoms. Thus, over-the-counter availability of antacids will further drive segment growth.
The global antacids market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific dominated the global antacids market in 2019 and is expected to grow at a highest pace through 2028.
Asia Pacific dominated the global antacids market in 2019 and is expected to grow at a rapid pace over the next few years. There is a strong growth potential in the emerging economies such as India, and China. The rapidly rising geriatric population, surge in prevalence of gastro esophageal reflux disease (GERD) in countries such as India and China provides large market for antacids.
North America held substantial share of the market in 2019. Increase in prevalence of gastrointestinal diseases along with surging volume of elderly patient pool in the U.S. are major factors expected to drive the demand for antacids in the region. For instance, about 15%-30% of the Americans were suffering from GERD in the country according to National Institute of Diabetes and Digestive and Kidney Diseases. Moreover, presence of key industry players offering wide range of antacids in the U.S. will drive the growth of antacids market in the future.